SCHEMBL3460017

SCHEMBL3460017

O=C1C(Cc2c(Cl)cc(OCc3ccccc3)cc2Cl)CCN1C1CCc2nc[nH]c2C1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.39
ADRA1A P35348 5/20 0.38
IP6K1 Q92551 1/20 0.36
HRH3 Q9Y5N1 4/20 0.35
XIAP P98170 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CYP2D6 P10635 2/20 0.34
S1PR1 P21453 1/20 0.34
PRKX P51817 1/20 0.34
ACVR1 Q04771 1/20 0.34
S1PR5 Q9H228 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3453691 0.94 HSD11B1 (0.39) HSD11B1ADRA1AIP6K1HRH3XIAP
SCHEMBL2207838 0.87 HSD11B1 (0.38) HSD11B1HRH3XIAPCYP2D6S1PR1
SCHEMBL2203408 0.86 HSD11B1 (0.39) HSD11B1HRH3XIAPCYP2D6S1PR1
SCHEMBL2206813 0.86 HSD11B1 (0.39) HSD11B1HRH3XIAPCYP2D6S1PR1
SCHEMBL2203404 0.86 HSD11B1 (0.39) HSD11B1HRH3XIAPCYP2D6S1PR1
SCHEMBL3454689 0.85 ADRA1A (0.37) HSD11B1ADRA1A
SCHEMBL3453433 0.85 ADRA1A (0.37) HSD11B1ADRA1A
SCHEMBL3453429 0.85 ADRA1A (0.37) HSD11B1ADRA1A
SCHEMBL3453486 0.81 ADRA1A (0.38) HSD11B1ADRA1A
SCHEMBL210102 0.81 HSD11B1 (0.48) HSD11B1HRH3NPC1RAB9ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029576-B1 CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-06-19 EP disclosed
US-7820659-B2 Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-10-26 US disclosed
US-20090088428-A1 CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-02 US disclosed
EP-2029576-A1 CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-03-04 EP disclosed
WO-2007124329-A1 CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088428-A1 CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885ADRA1A 467/4885IP6K1 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.